• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    IsoPlexis to Report Third Quarter 2022 Financial Results on November 10, 2022

    10/19/22 7:00:00 AM ET
    $ISO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $ISO alert in real time by email

    BRANFORD, Conn., Oct. 19, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced it will report financial results for the third quarter 2022 before market open on Thursday, November 10, 2022. Company management will be webcasting a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time.

    Live audio of the webcast will be available on the "Investors" section of the company website at: www.isoplexis.com. The webcast will be archived and available for replay after the event.

    About IsoPlexis

    IsoPlexis is empowering labs to leverage the cells and proteome changing the course of human health. Its platforms provide insights into how multi-functional immune cells communicate and respond, assisting researchers in understanding and predicting disease progression, treatment resistance and therapeutic efficacy.

    IsoPlexis has been named Top Innovation or Design by The Scientist Magazine, Fierce, BIG Innovation, Red Dot and multiple others. The IsoPlexis platform is used globally by researchers, including those at the top 15 global pharmaceutical companies by revenue and 78% of leading U.S. comprehensive cancer centers.

    Investor Contact

    [email protected]

    Press Contact

    [email protected]



    Primary Logo

    Get the next $ISO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ISO

    DatePrice TargetRatingAnalyst
    2/15/2022$17.00 → $12.00Overweight
    Morgan Stanley
    1/27/2022$20.00 → $15.00Outperform
    SVB Leerink
    11/19/2021$24.00Outperform
    Evercore ISI Group
    11/11/2021$17.00 → $20.00Outperform
    SVB Leerink
    11/2/2021$17.00Outperform
    SVB Leerink
    11/2/2021Outperform
    Cowen & Co.
    11/2/2021$16.00Overweight
    Morgan Stanley
    More analyst ratings